USA£º(540) 808-3925
China£º400-117-0038
Spain
Shopping Cart
Sign in \ Register
Crizotinib (CAS: 877399-52-5)
Catalog #£ºEBC51046
  SKU-Pack Size Availability Size Price
EBC51046-1ML In Stock 1mL(10mM in DMSO) €113.10
EBC51046-5MG In Stock 5mg €113.10
EBC51046-10MG In Stock 10mg €165.10
EBC51046-50MG In Stock 50mg €516.10
EBC51046-100MG In Stock 100mg €776.10
If you want to get a larger packsize, Please contact your local distributor or
email us atinfo@ebiocell.com
Please Select The Country You Are In To Find Your Local Distributor.
Betaclonal Phone£º+34 (0)91 471 6763
29/1 Lomonosovsky Pr, E-mail£ºtech@betaclonal.com
Spain Madrid, Spain Web£ºwww.betaclonal.com
Product Information
Synonym(s) PF 02341066, PF 2341066
Chemical Name 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinaminephenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
Application Crizotinib is a Potent c-MET/ALK inhibitor
CAS Number 877399-52-5
Purity ¡Ý99.0%
Molecular Weight 450.34
Molecular Formula C21H22Cl2FN5O
SMILES ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C
Target & IC50 ALK: IC50=24 nM
c-Met: IC50=11 nM
Solubility DMSO: 4.5 mg/mL (10 mM)
2eq.HCl: 45 mg/mL (100 mM)
Preparing Stock Solutions
ConcentrationSolventMass 1 mg 5 mg 10 mg
1 mM 2.2205 ml 11.1027 ml 22.2054 ml
5 mM 0.4441 ml 2.2205 ml 4.4411 ml
10 mM 0.2221 ml 1.1103 ml 2.2205 ml
50 mM 0.0444 ml 0.2221 ml 0.4441 ml
Shipping Gel Pack
Storage Store at -20¡ãC
Research Use For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use.
Product Description

Crizotinib is an orally bioavailable agent belonging to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity. Crizotinib was approved For treatment of some non-small cell lung carcinoma (NSCLC) in the US, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and childre. Crizotinib inhibits the membrane receptor MET and activation of the MET signaling pathway, which may block tumor cell growth, migration and invasion, and tumor angiogenesis in susceptible tumor cell populations. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) . For the detailed information about the solubility of Crizotinib (PF-2341066) in water, the solubility of Crizotinib (PF-2341066) in DMSO, the solubility of Crizotinib (PF-2341066) in PBS buffer, the animal experiment£¨test£© of Crizotinib (PF-2341066),the in vivo,in vitro and clinical trial test of Crizotinib (PF-2341066),the cell experiment£¨test£© of Crizotinib (PF-2341066),the IC50, EC50 and Affinity of Crizotinib (PF-2341066).

Specific Protocols
>> Western Blotting Protocol >> Immunoprecipitation Protocol
>> Immunohistochemistry Protocol >> Immunofluorescence Protocol
>> Immunocytochemistry Protocol >> Flow Cytometry Protocol
>> ChIP Protocol >> ELISA Protocol
>> HPLC Protocol >> PCR Protocol
For Research Use Only, Not For Diagnostic Or Therapeutic Procedures.
Copyright 2015 EbioCell, Inc. All Rights Reserved. ¡¡±¸°¸ºÅ£º½òICP±¸2022005142ºÅ-1